Kairos Pharma grants $950K RSUs to executives; $227.5K cash bonuses for FY2024

Kairos Pharma, LTD.

Total RSU grant value $950K at $1.31/share, vesting Oct 8, 2026 with change-of-control acceleration.
CEO John S. Yu receives 190,840 RSUs ($250K) and $87.5K cash bonus for FY2024.
CSO Neil Bhomick gets 171,756 RSUs ($225K) and $50K cash bonus.
CFO Doug Samuelson gets 152,672 RSUs ($200K) and $50K bonus; VP R&D Ramachandran Murali also gets 152,672 RSUs ($200K) and $40K.
Independent directors Hyun Bae, Hansoo Keyoung, Rahul Singhvi each receive 19,084 RSUs worth $25K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.